← Eichor
Condition: Metastatic Prostate Adenocarcinoma Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Metastatic Prostate Adenocarcinoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

LUtetium-177 DOsimetry as a Predictive Biomarker of Response in Metastatic Prostate Cancer Patients Treated With PSMA Ra
Phase N/A · 1 location(s) · Jules Bordet Institute · NCT07370597Elective Adaptive Radiation With SBRT for Improved DurabilitY of Response
NA · 1 location(s) · University Health Network, Toronto · NCT06831032ARCTIC: Liquid Biomarkers in the Prospective Androgen Receptor Signaling Inhibitors (ARSI) Resistance Clinical Trials
Phase N/A · 3 location(s) · Duke University · NCT06141993PSMA PET for Surveillance After Focal Therapy
NA · 1 location(s) · University of Chicago · NCT07115914A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer
Phase 1 · 8 location(s) · Bristol-Myers Squibb · NCT06067841This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Tor
Phase 1 · 3 location(s) · Zumutor Biologics Inc. · NCT06451497A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male P
Phase 1/Phase 2 · 25 location(s) · AstraZeneca · NCT07192614Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer
Phase 1 · 8 location(s) · Acerand Therapeutics (Hong Kong) Limited · NCT06801236ABlative Radiotherapy (for) Unfavorable Prostate Tumors 2.0
Phase N/A · 1 location(s) · University of Milano Bicocca · NCT07407608The Impact of Metastatic Directed Radiotherapy (MDRT) on Oligoprogressive Castration Resistant Prostate Cancer (CRPC)
Phase 2 · 2 location(s) · University Medical Center Groningen · NCT07038304Imaging of Solid Tumors Using 18F-TRX
Phase 1 · 1 location(s) · Rahul Aggarwal · NCT06942104A Study of MGC026 in Participants With Advanced Solid Tumors
Phase 1 · 12 location(s) · MacroGenics · NCT06242470Measuring Oncological Value of Exercise and Statin
Phase 3 · 1 location(s) · Tampere University Hospital · NCT05796973Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer
Phase 2 · 1 location(s) · City of Hope Medical Center · NCT04734730Study of DCC-2812 in Participants With Advanced Genitourinary Cancers
Phase 1 · 6 location(s) · Deciphera Pharmaceuticals, LLC · NCT06966024Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Phase 1 · 10 location(s) · Nammi Therapeutics Inc · NCT06582017Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
Phase 3 · 338 location(s) · SWOG Cancer Research Network · NCT03678025Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T
Phase 2 · 31 location(s) · Dendreon · NCT06134232Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Can
Phase 2 · 13 location(s) · National Cancer Institute (NCI) · NCT05691465Dual-target PSMA/PSCA CAR-NK Cells in Advanced Prostate Cancer
Phase 1 · 1 location(s) · Beijing Biotech · NCT07641049Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07523529Study of HLD-0915 in Patients With Metastatic Prostate Cancer
Phase 1/Phase 2 · 12 location(s) · Janssen Research & Development, LLC · NCT06800313Bintrafusp Alfa (M7824) and PDS01ADC Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults
Phase 1 · 1 location(s) · National Cancer Institute (NCI) · NCT04235777Sacituzumab Tirumotecan in Combination With Tagitanlimab in the Treatment of Aggressive Variant Prostate Cancer (AVPC) a
Phase 2 · 1 location(s) · Tianjin Medical University Second Hospital · NCT07179783SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Phase N/A · 68 location(s) · Massive Bio, Inc. · NCT03452774Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors
Phase 1 · 20 location(s) · SystImmune Inc. · NCT07080242Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME T
NA · 1 location(s) · M.D. Anderson Cancer Center · NCT04693377Talazoparib Plus Enzalutamide After Progression to Abiraterone in Metastatic Prostate Cancer: (TEAM PC)
Phase 2 · 12 location(s) · Fundacion Oncosur · NCT06582628177^Lu-PSMA-617 in Combination With Sipuleucel-T for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Phase 1 · 1 location(s) · City of Hope Medical Center · NCT07219147Trial Targeting Gut Bacterial Androgen Production to Reverse Therapeutic Resistance to Abiraterone in Patients With Meta
Phase 2 · 1 location(s) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · NCT06616597
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.